Delving into the Latest Updates on HRS-4508 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

HRS-4508

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Locally Advanced Lung Non-Small Cell CarcinomaAdvanced Malignant Solid NeoplasmMetastatic Solid Tumor

Inactive Indication-

Originator Organization

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Active Organization

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combination with other anti tumor therapy in subjects with solid tumor ; to evaluate HRS4508 DLT, MTD and RP2D, to evaluate the incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0), to evaluate ORR by researchers based on RECIST v1.1, to evaluate the pharmacokinetic (PK) characteristics of HRS-4508 SHR-1811, Capecitabine.

Start Date01 Oct 2025

Sponsor / Collaborator

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

NCT07003321

/ RecruitingPhase 2

Study on Efficacy and Safety of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer

The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.

Start Date12 Sep 2025

Sponsor / Collaborator

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

NCT06598735

/ Not yet recruitingPhase 1

An Open, Multicenter Phase I Study of Safety, Tolerability, and Pharmacokinetics of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors

The study is being conducted to evaluate the efficacy and safety of HRS-4508 in subjects with advanced or metastatic solid tumors and explore the reasonable dosage of HRS-4508.

Start Date30 Sep 2024

Sponsor / Collaborator

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

100 Clinical Results associated with HRS-4508

Login to view more data

100 Translational Medicine associated with HRS-4508

Login to view more data

100 Patents (Medical) associated with HRS-4508

Login to view more data

100 Deals associated with HRS-4508

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 2	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	12 Sep 2025
Advanced Malignant Solid Neoplasm	Phase 1	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	30 Sep 2024
Metastatic Solid Tumor	Phase 1	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	30 Sep 2024